äºé²å»åŠãå¥åº·èšºæãçæŽ»ç¿æ £æ¹åã«é¢ããæ å ±äº€æ
50
ã¡ã³ããŒ
36
æçš¿
å¥åº·èšºæã®çµæãåå¿è åãã«ãŸãšããŸãããHbA1cãLDLã³ã¬ã¹ãããŒã«ãeGFRãªã©ã®åºæºå€ãšãèŠæ³šæã®æ°å€ã«ã€ããŠã䞻治å»ããæããŠããã£ãå®è·µçãªã¢ããã€ã¹ãå ±æããŸãã幎ã«äžåºŠã®å¥èšºãæå€§é掻çšããŸãããã
é«è¡å§ãšäžæãä»ãåãããã®çæŽ»ç¿æ £ãèŠçŽãäžãæžå¡©ãé©åºŠãªéåãã¹ãã¬ã¹ç®¡çã®3ã€ãç¹ã«å¹æã宿ããŠããŸããã¿ãªããã®å·¥å€«ãæããŠãã ããïŒ
åšå® å€åã§éåäžè¶³ãæ·±å»ã ã£ãã®ã§ãèªå® ã«ãããžã ãäœããŸããããšã¬ãããããã³ãã«ãæžåããŒã®3ç¹ã»ããã§ååãæ¯æ¥30åã®éåã3ã¶æç¶ããçµæãåçž®æè¡å§ã145â128ã«æ¹åããªãããªã®å°éå®¶ãšããŠãèªä¿¡ãæã£ãŠããããããŸãã
åšå® å€åãå¢ããŠéåäžè¶³ãæ·±å»ã ã£ãã®ã§ãèªå® ã«ãããžã ãäœããŸããããšã¬ãããããã³ãã«ãæžåããŒã®3ç¹ã»ããã§ååãæ¯æ¥30åã®éåã§è¡å§ãå®å®ããŠããŸãã
ã¡ããã«ãã³ã飲ã¿å§ããŠ3ã¶æãHbA1cã7.2â6.5ã«æ¹åããŸãããé£äºç®¡çãšäœµçšããã®ã倧äºã ãšå®æãç¹ã«é£åŸã®è¡ç³å€ã¹ãã€ã¯ãæããããã®ã宿ããŠããŸããç®¡çæ é€å£«ããã®é£äºæå°ãšã®çµã¿åããã广çã§ãããåãè¬ãæçšããŠããæ¹ãæ å ±äº€æããŸãããïŒ
ã¡ããã«ãã³ã飲ã¿å§ããŠ3ã¶æãè¡ç³å€ãå®å®ããŠããŸãããé£äºç®¡çãšäœµçšããã®ã倧äºã ãšå®æããŠããŸããåãè¬ãæçšããŠããæ¹ãæ å ±äº€æããŸãããïŒ
æ°å¹Žåã®å¥åº·èšºæã®çµæããŸãšããŠèŠæ¯ã¹ãããã«ããŠããŸããäžå¹Žã ãã ãšãåºæºå€å ã ãã倧äžå€«ãã§çµãã£ãŠããŸããŸããã䞊ã¹ãŠã¿ããšå°ããã€å€åããŠããé ç®ã«æ°ã¥ããŸããæ©ãã«ç掻ãèŠçŽããã£ããã«ãªããŸãããåãããšãããŠããæ¹ã¯ããŸããã
æ¯æ¹ã®ç¥æ¯ãšæ¯ãäž¡æ¹ãšãã¢ã«ããã€ããŒåãšèšºæãããŠãèªåã40代åŸåã«å ¥ã£ãã®ã§ãæ¬æ°ã§äºé²ãèããŠããŸãã Lancetã®ãä¿®æ£å¯èœãª12ã®ãªã¹ã¯å åãã¯äžéãèªã¿ãŸããããå ·äœçã«äœããæãã€ãããåªå é äœãã€ãã«ããã§ãã éåã»ç¡ç ã»èŽèŠã±ã¢ã»ç³å°¿ç 管çããããäžäœã§ãããçãããå®¶ææŽããã§å®éã«ãã£ãŠãã察çãããã°æããŠãã ããããµããªç³»ã®è©±ã¯ååã«æççã«èªãã§ããã®ã§ãçæŽ»ç¿æ £ããŒã¹ã®å®äœéšãèãããã§ãã
æ¯å¹Žã®å¥åº·èšºæã§LDLã³ã¬ã¹ãããŒã«ãåºæºå€ãå°ãè¶ ããŠããŠããã£ãšæ§åèŠãšèšãããŠããŸããåçå»çãæ°è¬ã®ãã¥ãŒã¹ã远ã£ãŠãããšãçµå±ã®ãšããæ¥ã ã®äºé²ãäžçªå°å³ã ãã©å€§äºãªãã ãªãšæããŸãã é£äºãšéå以å€ã§ãçãããç¶ããŠããäºé²ç¿æ £ãããã°åèã«ãããã§ãã
å æ¥ãå®å®¶ã®æ¯ã®å¥åº·èšºæã®çµæãäžç·ã«èŠãæ©äŒããããŸããã èªåãäŒç€Ÿã§åããŠãããã®ãšæ¯ã¹ããšãé ç®ã®çްãããå šç¶éããã§ãããæ¯ã®æä»£ã¯ããšããããäžéãããšããæãã ã£ãã®ããä»ã¯çæŽ»ç¿æ £ã«åãããŠéžã¹ãæ€æ»ãå¢ããŠããå°è±¡ã§ãã éžæè¢ãå¢ããã¶ããäœãåããã°ããã®ãè¿·ãã®ãäºå®ã§ãã¿ãªããã¯æ€èšºã®é ç®ãã©ãããåºæºã§éžãã§ããŸãããå®¶æã®è©±ãå«ããŠèããŠã¿ããã§ãã
æ¯å¹ŽLDLãå°ããã€äžãã£ãŠããŠã忀æ»ã§ã¯ãªãããã©çµé芳å¯ãšèšãããŸããã é£äºãšéåã§æ§åãèŠãŠããã®ã§ãããæ°å€ã®äžäžã«äžåäžæããŠããŸããŸãã çæŽ»ç¿æ £ã®æ¹åã£ãŠã©ã®ãããã®æéã§çµæãèŠãããã®ãªãã§ãããããæ°é·ã«ãããããªããšã¯æãã€ã€ã
ãäœãèµ·ãããã Coinbase CEOãã©ã€ã¢ã³ã»ã¢ãŒã ã¹ããã³ã°æ°ãå ±å嵿¥ããç±³NewLimitãã4å3500äžãã«ã調éãããäŒæ¥äŸ¡å€ã¯31åãã«ãååã©ãŠã³ããã1幎足ããã§3åè¶ ã«èšããã ãFounders Fundãäž»å°ããThrive Capitalãªã©ãåå ããŠãããæ¥å¹Ž(2027幎)ãèèã®çްèãè¥ãç¶æ ã«æ»ãæ²»çã®åã®èšåºè©Šéšãäºå®ããŠããã ãéšåãªããã°ã©ãã³ã°ãšã¯ã iPS现èãã€ãããšãã«äœ¿ã4ã€ã®éºäŒå(å±±äžå å)ã现èã«çæéã ãåãããã©ã®éºäŒåã䜿ãããæ±ºããç®å°(ãšãã²ãã )ãè¥ãããã®ãã¿ãŒã³ã«æ»ããiPS现èã®ããã«å®å šã«åæåããã®ã§ã¯ãªããéäžã§æ¢ãã â ã ãããéšåããšåŒã°ããã现èã®çš®é¡ã¯è现èã®ãŸãŸãæèšã ããå·»ãæ»ãã€ã¡ãŒãžã ã ããªãä»ãè³éãéãŸãã®ãã åãè³ãã«åºãŠããäŒç€Ÿã¯ä»ã«ããããããŸã¹æ°ããåºè³ããAltos Labsã¯30åãã«èŠæš¡ããµã ã»ã¢ã«ããã³æ°ãæ¯ããRetro Biosciencesã¯è©äŸ¡é¡18åãã«ãåå¥ã®ç æ°ã§ã¯ãªãèåãã®ãã®ãæšçã«ãã â ãã®åžå Žã®å€§ããã«è³æ¬ãå åãããŠããæ§å³ã ã ãå·éã«èŠãã¹ãç¹ã éšåãªããã°ã©ãã³ã°ã§ããã§ã®æå¹æ§ã瀺ããããŒã¿ã¯ããŸã äžã€ããªããå±±äžå åã¯åããããããšè «çãäœãããããšãåç©å®éšã§ç¥ãããŠããããã©ãã§æ¢ããããã®å¶åŸ¡ãæå€§ã®æè¡èª²é¡ã«ãªãããããžã®æäžãå§ãŸã£ãã®ã¯ããäžéš(ç·å éãçãLife Biosciencesãªã©)ã§ãæå¹æ§ã®çããåºãã®ã¯ããããã ã åºå ž: STAT News(2026幎6æ2æ¥)/ MIT Technology Review(2026幎6æ12æ¥) â»æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã

Why âreprogrammingâ is the buzziest approach to reversing aging right now
Promising mouse studies and billions of dollars in funding are stoking excitement. But weâve been here before.
www.technologyreview.com
ãäžçåã®ãªããã°ã©ãã³ã°èšåºè©Šéšãå§åã Life Biosciences瀟ãéçºãããER-100ãããäžçã§åããŠéšåçãªããã°ã©ãã³ã°(现èã®è¥è¿ã)ã人äœã«è©Šãèšåºè©Šéšãžã®æ£è ç»é²ãéå§ããŸããã察象ã¯å€±æã«ã€ãªããèŠç¥çµçŸæ£ãLHON(ã¬ãŒããŒéºäŒæ§èŠç¥çµç)ãã®æ£è ã§ãã ãER-100ãšã¯ã å±±äžäŒžåŒ¥ææãiPS现èã®äœè£œã§çšãããå±±äžå åãã®ãã¡3ã€(OCT4ã»SOX2ã»KLF4)ãçŒã«å±ããå·ã€ããç¶²èç¥çµç¯çްèãè¥ãç¶æ ã«ãªã»ããããããšãç®æãéºäŒåæ²»çã§ããåç©å®éšã§ã¯ããŠã¹ããµã«ã®èŠåãå埩ãããšå ±åãããŠããŸãã ããªãç»æçãã ãããŸã§èåã现èã¬ãã«ã§å·»ãæ»ãã¢ãããŒãã¯åºç€ç ç©¶ã«çãŸã£ãŠããŸãããä»åã¯FDAãIND(æ²»éšéå§ç³è«)ãæ¿èªããããã§å®å šæ§ãšå¹æã確ãããæ®µéã«å ¥ããŸããèŠç¥çµãšãããéããçµç¹ãããå§ããã®ã¯ããªã¹ã¯ãéå®ããããã®æ éãªèšèšã§ãã ãæåŸ ãšæ³šæç¹ã æåããã°ãç·å éãªã©ä»ã®èŠç¥çµçŸæ£ãããã«ã¯ä»ã®èåšã®èåé¢é£çŸæ£ãžã®å¿çšãèŠéã«å ¥ããŸãããã ãèšåºè©Šéšã¯å§ãŸã£ãã°ããã§ãæå¹æ§ãå®å šæ§ã確ç«ãããããã§ã¯ãããŸãããåæããŒã¿ã®å ¬éã«ã¯æ°å¹ŽãããèŠèŸŒã¿ã§ãã åºå ž:MIT Technology ReviewãLife Bioscienceså ¬åŒçºè¡š â»æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã

The first human test of a rejuvenation method will begin âshortlyâÂ
In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers.
www.technologyreview.com
ç¶ã60代ã§å¿çæ¢å¡ãèµ·ãããŠãããèªåã®åè硬åãªã¹ã¯ãæ°ã«ãªã£ãŠããŸãã LDLã³ã¬ã¹ãããŒã«ã¯å¥èšºã§åºãã®ã§ãããLp(a)ã¯å¥ãªãã·ã§ã³ã«ãªãããšãå€ããšèããŸãããäžçã«äžåºŠæž¬ãã°ãããéºäŒã§æ±ºãŸãé ç®ã ããšãããšãããŸã§ã¯èª¿ã¹ãã®ã§ãããå®éã«ãªãã·ã§ã³ã§ã€ããããšã®ããæ¹ãã³ã¹ãã®ç®å®ããçµæã䞻治å»ã«ã©ã掻ãããŠããã£ããæããŠããããªãã§ããããã
èåãã现èãè¥ãç¶æ ã«æ»ãââSFã®ãããªçºæ³ããã€ãã«äººã®äœã§è©ŠãããŸããã ãäœãèµ·ããã®ãã ç±³Life Biosciencesãã现èãªããã°ã©ãã³ã°æè¡ã䜿ã£ãäžçåã®äººäœèšåºè©Šéšã«ã€ããŠãFDAïŒç±³é£åå»è¬åå±ïŒããæ²»éšéå§ã®æ¿èªïŒIND clearanceïŒãååŸããŸããã察象ã¯éæŸé è§ç·å éãNAIONïŒéåèçæ§åéšèè¡æ§èŠç¥çµçïŒãªã©å 霢ã«äŒŽãèŠç¥çµã®ç æ°ã§ãè¬å€ãER-100ããçšããŸããæ£è ã®çµã¿å ¥ãã¯ããããå§ãŸã段éã§ãå®éã®æäžçµæã¯ãŸã å ±åãããŠããŸããã ããªããã°ã©ãã³ã°ãšã¯ã 京éœå€§åŠã®å±±äžäŒžåŒ¥ææãèŠã€ãããå±±äž4å åãã¯ãæçãã现èãåæç¶æ ã«æ»ãéºäŒåã®ã»ããã§ããä»åã¯ãã®ãã¡3å åïŒOSKïŒã ãã䜿ãã现èãå®å šã«åæåãããè¥ãé ã®åãã«è¿ã¥ãããéšåçãªããã°ã©ãã³ã°ããçããŸããåç©å®éšã§ã¯èŠç¥çµã®æ©èœå埩ãå ±åãããŠããŸããã ããªã泚ç®ãã ãããŸã§èåç ç©¶ã®å€ãã¯å¹é€çްèãåç©ã®æ®µéã§ãããä»åã¯ããã®ä»çµã¿ãäººã§æ€èšŒããéãåããŠå ¬åŒã«éãããäžæ©ã§ããå®å šæ§ãšå¹æã¯ããããå§ãŸã詊éšã§ç¢ºãããããŸãã åºå žïŒLifespan.ioïŒ2026幎2æ6æ¥ïŒ æ¬èšäºã¯æ å ±æäŸãç®çãšãããã®ã§ã蚺æãæ²»çæ¹éã¯å¿ ã䞻治å»ã«çžè«ããŠãã ããã

First Human Cellular Reprogramming Trial Cleared by the FDA
Life Biosciences' trial of cellular reprogramming aimed at age-related vision diseases has received a go-ahead from the FDA. We spoke with the companyâs CSO.
lifespan.io
çè·åž«ãããŠããŸãã å¥åº·èšºæã®çµæãåãåã£ãŠããã©ã®æ°å€ãæ°ã«ããã°ãããåãããªãããšãã声ãããèããŸããç§èªèº«ã¯ãå»å¹Žãšæ¯ã¹ãŠã©ãå€åãããããšãããå€åããèŠãããã«ããŠããŸãã1幎ã§å€§ããåããé ç®ãããã°ãçæŽ»ãæ¯ãè¿ããã£ããã«ããŠããŸãã çããã¯çµæã®ã©ããèŠãŠããŸããã
èŠç¥çµã®ç ç©¶ãèåç ç©¶ã®å ¥å£ã«ãªã£ãŠããããšãã話ãèªãã§æ°ã«ãªããŸããã ç®ã¯å€ããæ€æ»ããããããç ç©¶ã®å¯Ÿè±¡ã«ãªããããããšããäºæ ã¯äœãšãªããããã®ã§ãããç®ã§èµ·ããŠããããšãšäœå šäœã®èåã£ãŠãã©ã®ãããã€ãªãã£ãŠãããã®ãªãã§ãããããããŸã§çŽ æŽãªçåã§ãã
éºäŒåã®æ€æ»ã§ç æ°ã®ãªã¹ã¯ãæ©ãåããæä»£ã«ãªã£ãŠããŸããããããçºçåã«åãã£ãå ŽåãçæŽ»ç¿æ £ã§ã§ããããšã£ãŠã©ã®ããããããã§ãããã ãã¡ããç æ°ã«ãã£ãŠéããšã¯æããŸãããã ãæ²»çæ³ãåºãŠãããŸã§ã®éãé£äºãå®ææ€æ»ã§é²è¡ãé ããããããã®ããããšèããŠãååãã«èããããããããªãšæã£ãŠããŸãã
äºé²ã®èгç¹ã§åžè²©ã®éºäŒåæ€æ»ããããæ°ã«ãªã£ãŠããŸãã äœè³ªãçŸæ£ãªã¹ã¯ãåãããšããè§Šã蟌ã¿ã§ããã粟床ã䜿ãã©ãããæ£çŽããåãããŸãããå®éã«äœ¿ã£ãŠã¿ãŠã©ãã ã£ãããææ³ãèãããšå¬ããã§ãã
å®å®¶ã®èŠªãé«è¡å§ãšèšãããŠãèªåãé£ç掻ãèãããã£ããã«ãªããŸããããšããããå³åæ±ã®å¡©åãæžãããŠãå€é£ã®ãšãã¯éººé¡ã®ã¹ãŒããæ®ãããã«ããŠããŸããå°å³ã§ããäºã¶æãããã§å°ãäœã軜ããªã£ãæ°ãããŸããå®¶æã®ç æ°ããã£ããã«ç掻ãå€ããæ¹ãããŸããã
å é±Lancetã«æ²èŒãããå€§èŠæš¡ååãã³ããŒãç ç©¶ïŒn=502,536ã远跡æé12.4幎ïŒã®çµæãã·ã§ã¢ããŸãã äž»ãªç¥èŠïŒ ã»å°äžæµ·é£ã¹ã³ã¢äžäœ25%ïŒèº«äœæŽ»åã¬ã€ãã©ã€ã³éµå®çŸ€ â èªç¥çãªã¹ã¯40%äœäžïŒHR: 0.60, 95%CI: 0.53-0.68ïŒ ã»å°äžæµ·é£ã®ã¿ â 22%äœäž ã»éåã®ã¿ â 18%äœäž ã»äž¡æ¹çµã¿åããã广ã¯å ç®çã§ã¯ãªããçžä¹ç 泚ç®ãã¹ãã¯ãçžä¹å¹æãã®éšåã§ããé£äºãšéåãå¥ã ã«å®è·µãããããäž¡æ¹ãçµã¿åãããæ¹ãæããã«å¹æã倧ããã èšåºçŸå Žã§ã¯ããŸãã¯é£äºãããããŸãã¯æ©ãããšããããšæ®µéçã«æå°ããã¡ã§ãããã§ããã ãæ©æã«äž¡æ¹ã䞊è¡ããŠå§ããããšã®éèŠæ§ãè£ä»ãããã圢ã§ãã ç§ã®æ åœæ£è ããã«ãæ©éå ±æããããšæããŸãã
Mediterranean diet and physical activity in dementia prevention â The Lancet
A prospective cohort study of 502,536 participants showing synergistic effects of diet and exercise
www.thelancet.com
äºé²å»åŠã«èå³ããã£ãŠãã¿ãã³Dã話é¡ã«ããåºãŠããã®ã§ããã è¡æ¶²æ€æ»ã§æ°å€ã確èªããŠããè£å ããã®ãåºæ¬ã ãšãã話ãèããŸããã äžæ¹ã§ãæ¥æ¬äººã¯å šäœçã«äžè¶³ããã¡ãªã®ã§è»œãéãªãæ€æ»ãªãã§ãããããšããæèŠããã£ãŠæ··ä¹±ããŠããŸãã å®éã«ãã¿ãã³Dè£å ãåãå ¥ããŠããæ¹ãæ€æ»ã¯ãããŸããã? ã©ã®ãããã®éã§å§ããŸããã? (ããã¯å人ã®äœéšè«ãåéããæçš¿ã§ãå»åŠçã¢ããã€ã¹ãæ±ããŠããããã§ã¯ãªãã§ããæçµå€æã¯å»åž«ã«çžè«ããŸãã)
å®å®¶ã®èŠªãæè¿äœèª¿ã厩ããã¡ã§ããã£ãšæ©ãããçæŽ»ç¿æ £ã«æ°ãã€ããŠããã°ãšããè©±ãæ¬äººãšãããŠããŸãã èªåãååãéããŠãä»ããã§ãã§ããäºé²ã£ãŠäœã ãããšèããããã«ãªããŸãããæŽŸæãªããšã§ã¯ãªããç¶ããããå°ããªç¿æ £ã®ã»ããçµå±å¹ãã®ããªãšæè¿ã¯æã£ãŠããŸããåããããªå¹Žä»£ã®æ¹ã®äœéšè«ãèããŠã¿ããã§ãã
䞡芪ãšå åŒã®ã³ã¬ã¹ãããŒã«å€ãèããŠåã£ãŠãå®¶ç³»å³ã«æžãåºããŠã¿ãããç¶æ¹ã®ç¥ç¶ã»ç¶ã»åæ¯ã»èªåãå šå¡LDLãåºæºå€ã®åè¿ããã£ãŠããããå šå¡30代ããå¿è¡ç®¡ç³»ã®ã€ãã³ããããããšããã®ã«æ°ã¥ããŸããã å»åž«ã«çžè«ãããå®¶ææ§é«ã³ã¬ã¹ãããŒã«è¡ç(FH)ã®çãã匷ããšããããšã§ãéºäŒåŠçæ€æ»ã𿩿ããã®ã¹ã¿ãã³å°å ¥ã®è©±ã«ãªããŸããã æžããŠã¿ããŸã§ããã ããã¡ã¯è¡ãæ¿ãããããããã«æã£ãŠããã®ã§ãããçŽã«æžããšäžæ°ã«åãå€ãããŸããåãããã«å®¶æã®æ°å€ãæ°ã«ãªã£ãŠããæ¹ãäžåºŠå®¶ç³»å³ã«ããŠã¿ãããšãããããããŸãã
Natureã2æã«å ±ããéããæ¥æ¬ã§éçºäžã®å¹¹çŽ°èæ²»çè¬ãæ£åŒæ¿èªã«åããæçµæ®µéã«å ¥ã£ãŠããŸããæ¡ä»¶ä»ãæ¿èªããæ£åŒæ¿èªãžã®ç§»è¡ãšããŠãåçå»çã®å®çšåã«ãããæŽå²çãªãã€ã«ã¹ããŒã³ãšãªããŸãã èæ¯ïŒ ã»æ¥æ¬ã®åçå»çç補åã®æ¡ä»¶ã»æéä»ãæ¿èªå¶åºŠïŒ2014幎æœè¡ïŒ ã»ãããŸã§7åç®ãæ¡ä»¶ä»ãæ¿èªãååŸ ã»æ£åŒæ¿èªã«è³ã£ãã®ã¯éå®çã§ãå¶åºŠã®æå¹æ§ãè°è«ãããŠãã ä»åã®æçŸ©ïŒ 1. æ¡ä»¶ä»ãæ¿èªâæ£åŒæ¿èªã®æåã¢ãã«ãç¢ºç« 2. é·æå®å šæ§ã»æå¹æ§ã®ãªã¢ã«ã¯ãŒã«ãããŒã¿èç© 3. ä¿éºåèŒã«åããå»ççµæžæ§ã®è©äŸ¡ äžççµæžãã©ãŒã©ã ïŒWEFïŒããåçå»çã¯ã°ããŒãã«çµæžã®åªå 課é¡ããšäœçœ®ã¥ããŠãããæ¥æ¬ã®å è¡äºäŸãäžççãªãã³ãããŒã¯ã«ãªãå¯èœæ§ããããŸãã äºé²å»åŠã®èŠç¹ããïŒ åçå»çã¯ãæ²»çãã®ã€ã¡ãŒãžã匷ãã§ããã倿§çŸæ£ã®æ©æä»å ¥ãšããŠäºé²çã«æŽ»çšã§ããå¯èœæ§ããçµç¹ã®å£åãäžå¯éã«ãªãåã«ä»å ¥ãããäºé²çåçå»çããšããã³ã³ã»ãããä»åŸæ³šç®ããããããããŸããã
Japan gives green light to first-of-their-kind stem cell therapies
Japan has approved two stem cell-based therapies for treating Parkinsons disease and heart failure in a world first.
www.medicalnewstoday.com
æ é€ã®å匷ãããŠããŸãã è žå ç°å¢ã®è©±é¡ãå¢ããŠããã®ã§ãèªåã§ãçºé µé£åãæ¯æ¥å°ããã€åãããã«ããŠããŸããçŽè±ããšãŒã°ã«ããå³åæ±ããããç¶ããããã§ãã åçã«äœããå€ãã£ããšããããããéããå®å®ããããªããšããçšåºŠã®å®æã§ãããç¡çãªãç¶ããããŠããã®ãäžçªã ãšæã£ãŠããŸããçããã®ç¿æ £ãç¥ãããã§ãã
æ¯å¹Žå¥åº·èšºæãåããŠããŸãããçµæãããã£ãŠããåºæºå€å ãã©ããããšãå»å¹Žãšæ¯ã¹ãŠã©ããããããããèŠãããŠããŸããã æ¬åœã¯é ç®å士ã®é¢ä¿ããæ°å¹Žåäœã®åŸåã§èªãã»ããæå³ããããšèããããšããããŸããå°éç¥èããªããŠãèªåã§ã§ããç¯å²ã§ãããå°ãèžã¿èŸŒãã èŠæ¹ãããã°æããŠã»ããã§ãã
ããæè¿ã现èãè¥è¿ããããšãèåãå·»ãæ»ãã¿ãããªè©±é¡ãããç®ã«ããŸããæ£çŽããããããäžæ¹ã§ãã©ããŸã§ãæ¬åœã«äººã§å¹ãã®ãããŸã åç©ã®æ®µéãªã®ããåºå¥ãã€ããªããªã£ãŠããŸããã 詳ããæ¹ã«èãããã®ã§ããããããããªããã°ã©ãã³ã°ç³»ã®è©±ã£ãŠãä»ã¯ãå®å šæ§ã確ãããå ¥å£ããããã®çè§£ã§åã£ãŠããŸãã?éåºŠã«æåŸ ããããªãããã«ãããã®ã§ãçŸå®çãªè·é¢æãç¥ãããã§ãã
æ¯å¹Žå¥èšºãåããŠã¯ããã®ã§ãããçµæç¥šãå±ããŠãæ°å€ã®æå³ãããåãããªããŸãŸä¿ç®¡ããŠçµããã«ãªã£ãŠããŸãã åºæºå€ããå€ããé ç®ã«ã¯å°ãã€ãã®ã§ãããã ãèŠãŠãä»å¹Žã倧äžå€«ã ã£ããã§æžãŸããŠããŸãããã ãåºæºå€ã®äžã§ãå»å¹ŽããåããŠããé ç®ã¯ããã¯ãã§ãããããå€åã¯èªåã§äžŠã¹ãŠã¿ãªããšæ°ã¥ããªãã§ãããã çããã¯çµæç¥šãã©ã管çããŠããŸãããã¢ããªã«å ¥ããŠããæ¹ãçŽã®ãŸãŸäžŠã¹ãŠããæ¹ãããããã®ããæ¹ãèããŠã¿ããã§ãã
ãã®ã³ãã¥ããã£ãããèŠãŠããã®ã§ãããéºäŒåæ²»çã®è©±é¡ãšäºé²å»çã£ãŠä»åŸã€ãªãã£ãŠãããã§ããããã çºäœãæãããçç¶ãæãããšããæ²»çã®è©±ãå€ãå°è±¡ã§ããããããçºçåã®ãªã¹ã¯æ®µéã«ä»å ¥ããæ¹åã«ãåºããã®ããçŽ äººã®çŽ æŽãªçåã§ãã詳ããæ¹ã®èŠç«ãŠãèããŠã¿ããã§ãã